GDC-0575

• UNSPSC Description:

  GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC50 of 1.2?nM.

• Target Antigen:

  Checkpoint Kinase (Chk)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/GDC-0575.html

• Purity:

  99.50

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL

• Smiles:

  O=C(C1CC1)NC2=CNC3=NC=C(Br)C(N4C[C@H](N)CCC4)=C32

• Molecular Weight:

  378.27

• References & Citations:

  [1]Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Mar 13. doi: 10.1158/1078-0432.CCR-17-2701.|[2]Laroche-Clary A, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29(4):1023-1029.|[3]Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8(1):1679.Mol Cancer Res. 2020 Jan;18(1):91-104.|Mol Cancer. 2024 Apr 29;23(1):86.|Nat Commun. 2020 Jan 8;11(1):123. |Neurotherapeutics. 2022 Mar;19(2):570-591.|Research Square Preprint. 2024 Nov 06.|bioRxiv. 2023 Feb 7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  1196541-47-5